Recent Updates
Recently added Catalysts

VK3019

Phase 1

Obese Adults | Small molecule | Metabolic |Viking Therapeutics, Inc.|Last Updated: Sep 29, 2026

Target and mechanism

Molecular targetAmylin Receptor
Target classReceptor
ModalitySmall molecule

Also known as SC VK3019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment56

FDA Designations

No designations recorded

Clinical trial landscape

VK3019 · 1 trial · 1 indication

Phase 1 1
NCT07846033A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesObese Adults
RECRUITING56 Analytics
PHASE1RECRUITING
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
Obese Adults
NCT0784603356
Unlock trial analytics

Study Endpoints

Primary Endpoints

Evaluate the safety of single doses of subcutaneous administration of VK3019
36 days

-Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

Secondary Endpoints

Evaluate the Pharmacokinetic profile of single doses of subcutaneous administration of VK3019
36 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
VK3019 Dose Level 1EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 2EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 3EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 4EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 5EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK 3019 Dose Level 6EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 7EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously

Interventions

NameTypeDescription
SC VK3019DRUGSingle dose VK3019
Matching placeboDRUGSingle dose matching placebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). * Participants must be medically healthy, with no significant medical history, have no clinically significant abnormali...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 29, 2026NCT07846033NEW_TRIAL: changed
LOWSep 29, 2026NCT07846033NEW_TRIAL: changed

Other drugs targeting Amylin Receptor

ACCG-2671 GPCR· PHASE1 LY3841136 LLY· PHASE2

Explore more on BiopharmaWatch

Viking Therapeutics, Inc. (VKTX)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with VCompanies A to ZEvery biotech and pharma company we track